Pre-NDA Meeting Briefing Document — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The briefing book for the Pre-NDA/Pre-BLA meeting with the FDA.
Why it exists. Shortly before filing the marketing application, the sponsor and FDA agree on the format, content, and any outstanding issues of the planned submission, reducing the risk of a Refuse-to-File. This book previews the application.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. —
Pre-NDA Meeting Briefing Document — GLPI-103
| Field | Value |
|---|---|
| Document ID | MTG-PRENDA |
| Version | 1.0 |
| Status | Final (portfolio) |
| Meeting type | Type B (Pre-NDA) — FDA [MOCK] |
| Compound | GLPI-103 (GLP-1 / Apelin [APJ] receptor dual agonist) |
| Sponsor | Virtual Biopharma Inc. |
| Standard(s) | 21 CFR 312.47 · FDA Formal Meetings Guidance (PDUFA VII) · ICH M4 (CTD) · M8 (eCTD) |
| Confidentiality | Confidential |
[MOCK]Briefing document supporting a Pre-NDA meeting to align on the content, format, and organization of the planned NDA, and to resolve outstanding review-readiness questions.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-30 | Regulatory Affairs | Initial Pre-NDA briefing document |
1. Meeting Objectives
To confirm that the planned NDA content and format are acceptable to support filing and review, including the adequacy of the efficacy/safety datasets, the integrated summaries, the CMC package, and the proposed labeling and risk-management approach.
2. Summary of Pivotal Results (GLPI103-301)
Both GLPI-103 formulations were superior to oral semaglutide on HbA1c CFB at Week 52 (IV −0.68%, Oral −0.34%; both p<0.001), with greater weight reduction (−14.5 / −10.3 vs −7.6 kg) and higher responder rates. Safety was class-consistent and gastrointestinal-predominant, with a tolerability trade-off (nausea higher in the IV arm, 32.3% vs 21.4%, p=0.003) managed by titration; 10 SAEs and 2 deaths (none treatment-related); no hepatotoxicity (eDISH) (CSR-301; M2.7.3/2.7.4).
3. Planned NDA Content and Format
eCTD Modules 1-5: full CTD Module 2 summaries (2.3-2.7), Module 3 (CMC, peptide drug substance + IV/oral products), Module 4 (nonclinical), Module 5 (CSR-301 + integrated summaries ISE-301/ISS-301 + early-phase CSRs); SDTM/ADaM datasets with Define-XML 2.1, ADRG/SDRG, and ARM (M5; DEF-301).
4. Datasets and Standards
CDISC-conformant SDTM and ADaM, validated (Pinnacle 21-equivalent conformance: 0 errors); reproducible analysis pipeline with reconciliation of all reported figures to source outputs (DEF-301; verification gates).
5. Questions for the Agency
- Does the Agency agree that the efficacy and safety data from the single pivotal study, supported by the integrated summaries, are adequate to support the proposed indication?
- Does the Agency agree with the content and format of the proposed eCTD submission, including the Module 2 summaries and the dataset/Define-XML/ADRG package?
- Does the Agency concur with the proposed labeling approach, including the boxed warning for thyroid C-cell tumors and the presentation of the IV vs oral tolerability trade-off?
- Does the Agency agree that the proposed REMS/risk-management approach (routine risk minimization + Medication Guide) is appropriate, without additional REMS elements?
- Does the Agency agree that the CMC package (including the SNAC permeation-enhancer justification and stability data) supports filing?
- Are there any datasets, analyses, or bridging information the Agency would require to be included to ensure a fileable, reviewable application?
6. Proposed Agreements
Sponsor seeks confirmation on Questions 1-6 to finalize the NDA for submission within ~90 days of the meeting.
Comments (0)
No comments yet. Be the first to say something!